Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

Revista Medica de Rosario, established in 1947 and currently published by the CIRCULO MEDICO DE ROSARIO, serves as a vital platform for disseminating research and advancements in the field of medicine. This Open Access journal, which transitioned to an open-access model in 2008, provides researchers and practitioners from around the globe with unrestricted access to its content, promoting the sharing of knowledge and fostering collaboration. Although it currently holds a Q4 rank in Medicine (miscellaneous) with a Scopus classification placing it in the 17th percentile among general medicine journals, its commitment to improving clinical practice and medical research in Argentina and beyond remains unwavering. In an era of rapid scientific advancement, Revista Medica de Rosario plays a crucial role in curating a diverse array of articles, from original research to reviews, aimed at enhancing understanding and innovation in the medical community. Situated in the vibrant city of Rosario, Argentina, the journal continues to evolve and adapt, making it an essential resource for students, professionals, and researchers alike.

Global Journal of Medical Pharmaceutical and Biomedical Update, published by SCIENTIFIC SCHOLAR LLC, is a premier platform dedicated to advancing knowledge in the fields of medicine, pharmaceuticals, and biomedical sciences. With an E-ISSN of 2765-8910, this journal aims to foster innovative research and insightful discussions by providing open access to high-quality peer-reviewed articles. It serves as an invaluable resource for researchers, professionals, and students alike, ensuring that the latest advancements, methodologies, and findings are accessible to a diverse audience. Located at 50, Woodgreen Dr, Pittsford, NY 14534, the journal prioritizes the dissemination of critical information that addresses the evolving challenges faced in healthcare and biomedical research, ultimately contributing to the betterment of global health outcomes.

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

The New England Journal of Medicine (NEJM), published by the Massachusetts Medical Society, stands as a beacon of excellence in the field of medicine. With an impressive impact factor and a prestigious rank of #2 out of 636 in General Medicine, NEJM is recognized in the Q1 category for its significant contributions to medical research and clinical practice since its inception in 1945. The journal is renowned for publishing groundbreaking studies, reviews, and commentaries that influence clinical guidelines and healthcare policies worldwide. While the journal is not open access, it provides pivotal resources that are essential for researchers, healthcare professionals, and students looking to stay abreast of the latest developments in medicine. With a commitment to advancing medical knowledge, NEJM plays a crucial role in bridging the gap between laboratory research and clinical application.

Bulletin of Russian State Medical University, published by the esteemed PIROGOV RUSSIAN NATL RESEARCH MEDICAL UNIV, serves as a crucial platform for advancing the field of medicine, particularly in the context of Russian healthcare advancements. With an ISSN of 2500-1094 and an E-ISSN of 2542-1204, this journal has emerged as a valuable resource for researchers, professionals, and students alike, enriching the academic landscape since its inception. Although categorized in the Q4 quartile for Medicine (miscellaneous) and currently ranked #385 out of 636 in the Scopus database, its ongoing commitment to disseminating vital research and clinical studies positions it as a respected, though evolving, contributor to the global medical community. Operating without an open-access model, it ensures the dissemination of quality-controlled scientific information while maintaining professional integrity. Spanning the intersecting domains of healthcare practices and medical science, the journal strives to provide insights and promote discussions that address contemporary challenges in the field, making it an essential read for anyone looking to stay at the forefront of medical research and practices in Russia and beyond.

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

The Journal of Hepatocellular Carcinoma is a pivotal open-access publication dedicated to advancing the field of hepatocellular carcinoma research. Published by DOVE MEDICAL PRESS LTD since 2014, this journal seeks to disseminate high-quality articles that explore innovative treatments, clinical trials, and emerging research in the context of liver cancer. With its ISSN: N/A and E-ISSN: 2253-5969, the journal is optimized for a global audience, ensuring accessibility to a broad spectrum of researchers, healthcare professionals, and students engaged in oncology and hepatology. While its Scopus ranking places it in the lower quartiles of the respective fields, the journal continues to strive for growth and visibility in a rapidly evolving landscape. The Journal of Hepatocellular Carcinoma is an essential resource for anyone seeking to enhance their understanding of liver diseases and contribute to the fight against hepatocellular carcinoma.

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.